Regulatory Filings • Mar 19, 2020
Regulatory Filings
Open in ViewerOpens in native device viewer
Photocure ASA: Market update
Oslo, Norway, 19 March 2020: The management of Photocure ASA (OSE:PHO) is
following the Covid-19 situation closely and has implemented strict measures to
ensure the safety of patients, customers, employees and business partners while
maintaining an uninterrupted level of service and supply.
"The pandemic brings massive hardship to those affected by the virus, to
families, communities and business. I would like to express our gratitude to all
healthcare professionals fighting this disease around the globe. Our main
priority is to ensure the uninterrupted supply of Hexvix[®]/Cysview[®], in
addition to maintaining our operations under a new framework. We are following
the situation very closely and have implemented strict measure to ensure the
safety of patients, customers, colleagues and partners. Scheduled bladder cancer
treatments are vital to the patient care and most procedures are being performed
as planned, with some postponements. However, we must expect this pandemic to
affect the healthcare systems as the burden of managing the virus increases in
the coming weeks and months," says Daniel Schneider, President & Chief Executive
Officer of Photocure.
Photocure's production of Hexvix/Cysview is running at full capacity with no
disruptions.
"There has been no disruption in our production schedules or shipments. Should
we experience a temporary disruption, we have current inventory of
Hexvix/Cysview that will last us to the end of 2020. Our key focus is to
provide an uninterrupted service in treating patients with bladder cancer. In
light of the seriousness of the current global health care crisis, the evolving
circumstances will require a different way of working between our company and
the health care providers we partner with. We intend to keep the lines of
communications open and we plan to offer a variety of means to keep Blue Light
Cystoscopy with Hexvix/Cysview in the forefront of patient care", says
Schneider.
Photocure has a strong cash position and carries no interest-bearing debt.
"Photocure has a strong underlying sales momentum in the U.S when returning to a
normalized business environment, providing a solid platform for long-term
growth. Short term business development and operations will be affected by this
unprecedented crisis in various ways, but we remain confident in the significant
commercial opportunities in the U.S. and reiterate our long-term ambitions",
Schneider concludes.
ENDS
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: [email protected]
Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: [email protected]
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.